KBR

[Interview with Global Pharma Leaders] 'Merck Biopharma Korea focusing on rare disease patients neglected due to small numbers'

Triferic registered in patented drugs, Jeil to sell it exclusively in Korea

Will Yoon government raise Covid’s classification back to Class 1?

Celltrion sends trial plans for global P3 study for Actemra biosimilar

Policy Subvariants’ continuous appearances thwart Korea’s hope for early end to Covid-19 Korea’s health authorities have confirmed 13 additional cases of BA.2.12.1, an Omicron subvariant, raising the total BA.2.12.1 cases to 19.According to the Central Disaster and Saf...

ALL

1 HLB starts marketing ovarian cancer treatment in Germany

2 Shionogi drops Covid pill trial in Philippines, continues Korean study

3 Enhertu likely to replace Kadcyla in HER2-positive breast cancer treatment

4 This Stanford scientist is so into ‘smart toilet.’ Here’s why.

5 AUMC finds possibility of regenerating damaged, irrecoverable spinal nerve circuits

6 Celltrion Healthcare to sell all products directly in Europe

7 KAERI exports medical radioactive isotopes to US

8 Drug impurity issue spreads to schizophrenia treatments

[Column] A World We’ve Never Experienced Before: Installation of Closed-Circuit Televisions in Operating Rooms

[Column] How should new government increase funding for severe, rare disease drugs?

[Reporter’s Notebook] Why does Janssen need a PR department – or an offshoot -- in Korea?

Shortage of medical examiners causes high level of burnout

Undocumented migrants unable to get health services amid pandemic

‘Can rampant hatred amid Covid-19 be strategy to curb infection risk?’

[Interview with Global Pharma Leaders] 'Merck Biopharma Korea focusing on rare disease patients neglected due to small numbers'

[Special] 3billion aims to lead genetic diagnosis in global market

[Special Interview] Bayer, strong in CV, female health areas, is trailblazer in cell and gene fields, too